Antiviral 1,3-dioxolane nucleoside analogues
AssigneeEmory University
InventorsDennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
Life of this patent
Estimating the term…
Abstract
This invention includes the compounds 2'-deoxy-5-fluoro-3'-oxacytidine, (-)-2'-deoxy-5-fluoro-3'-oxacytidine, and (+)-2'-deoxy-5-fluoro-3+-oxacytidine, and pharmaceutically acceptable salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an HIV infection.
Claims7
(.+-.)-2'-Deoxy-5-fluoro-3'-oxacytidine.
(-)-.beta.-2'-Deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer.
(+)-.beta.-2'-Deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer.
A pharmaceutical composition that comprises 2'-deoxy-5-fluoro-3'-oxacytidine, its (-) or (+) enantiomer or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.
A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of .beta.-2'-deoxy-5-fluoro-3'-oxacytidine or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier.
A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of (+)-.beta.-2'-deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier.
A method for the treatment of HIV infection in human cells, comprising administering an HIV-effective amount of (-)-.beta.-2'-deoxy-5-fluoro-3'-oxacytidine as a resolved enantiomer or its pharmaceutically acceptable salt, optionally in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.